Today, health-care analysts David Williamson and Max Macaluso look at what investors need to know about Biogen's potential blockbuster drug BG-12. 

It looks as if investors will have to wait a little longer, as the drug has been delayed. Shares are down only moderately on the news, and investors really shouldn't be too worried. David explains why this isn't as bad as it seems, and why this drug could still be one of the biggest blockbusters ever.

David Williamson, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Biogen Idec. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.